A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 10 mg Once-daily in the Treatment of Non-Erosive Gastroesophageal Reflux Disease

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 10 mg Once-daily in the Treatment of Non-Erosive Gastroesophageal Reflux Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Vonoprazan (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 15 Nov 2017 Planned End Date changed from 9 Jun 2018 to 21 Apr 2018.
    • 14 Nov 2017 Planned primary completion date changed from 9 Jun 2018 to 21 Apr 2018.
    • 27 Dec 2016 Planned End Date changed from 31 May 2018 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top